The ACR says that ANA subserology testing in conditions such as rheumatoid arthritis is rarely justified. Many rheumatologists are not acting accordingly. Why not?
Veronica Hackethal MD
Two new strategies for breaking through the tangle of pathways to identify those most important to rheumatoid arthritis treatment converge on a shared goal: personalized medicine.
Acronym alert: European rheumatologists are proposing new subtypes of disease-modifying antirheumatic drugs, prompted by advances in methods of drug development.
With the FDA poised to issue guidance for mobile health app designers, this review includes several well-regarded apps for rheumatoid arthritis and mentions a few newcomers.